Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Milei Threatens Falkland Oil Firms With Sanctions 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Xiaomi Shares Jump on Europe EV Expansion Plan 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
MENLO PARK, Calif., Feb. 22, 2018 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017, on Friday, March 16, 2018, after the market close. Geron’s management will also host a conference call for analysts and investors on Monday, March 19, 2018, at 8:30 a.m. Eastern Time to discuss the company’s fourth quarter and annual results as well as recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 3564078. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available through the Investors section of our website at www.geron.com or at https://edge.media-server.com/m6/p/4hrpsmd2. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 20, 2018.
About Geron
Geron is a biopharmaceutical company supporting the clinical stage development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
